Radical excision versus local resection for primary rectal gastrointestinal stromal tumors. Cohort Study
- 8 April 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in International Journal of Surgery
- Vol. 77, 190-197
- https://doi.org/10.1016/j.ijsu.2020.03.068
Abstract
Background: Rectal gastrointestinal stromal tumor (GIST) is a rare digestive disease that originates in mesenchymal tissues and has malignant tendencies. At present, no standard treatment has been developed, and surgical approaches and the resection scope for rectal GISTs are controversial. Methods: The clinical, surgical, pathological and prognosis data of patients with primary rectal GIST in our center from January 2008 to January 2019 were retrospectively collected. The patients were divided into the radical excision (RE) and local resection (LR) groups. Results: A total of 537 GIST cases were collected, and 64 patients with primary rectal GIST were included in this study, including 25 cases in the RE group and 39 cases in the LR group. Tumor size (p = 0.013), distance from the anus (p = 0.038), National Institutes of Health (NIH) criteria (p = 0.001), preoperative adjuvant therapy (p = 0.016), postoperative adjuvant therapy (p = 0.028), blood loss (p = 0.048), operative time (p = 0.020) and the duration of hospitalization (p = 0.021) were statistically different between these 2 groups. The mean overall follow-up time was 46 months (range, 1–122 months). Disease recurrence was observed in 12 patients. No statistical differences were observed in 5-year disease-free survival (DFS) (93.3% vs 92.6%, p = 0.952) or overall survival (OS) (90.0% vs 91.6%, p = 0.832) between the RE group and the LR group. Conclusion: Our study showed that LR has a similar prognosis to that of RE with respect to DFS and OS. For appropriate cases, LR has the advantages of a short operative time, less bleeding, and a quick recovery. Especially when combined with neoadjuvant therapy, LR can also achieve better perioperative efficacy. Therefore, LR is an effective method for resection of rectal GISTs and warrants clinical endorsement.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province
- Guangzhou Science, Technology and Innovation Commission
This publication has 32 references indexed in Scilit:
- Clinicopathological Features and Prognostic Factors of Rectal Gastrointestinal Stromal TumorsJournal of Gastrointestinal Surgery, 2013
- Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of ImatinibAnnals of Surgical Oncology, 2012
- Surgical management of rectal gastrointestinal stromal tumorsJournal of Surgical Oncology, 2012
- Transvaginal resection of a rectal gastrointestinal stromal tumorSurgery Today, 2012
- Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild‐type gastrointestinal stromal tumours: a comprehensive genotype–phenotype correlation studyHistopathology, 2012
- Is Lymph Node Metastasis a Common Feature of Gastrointestinal Stromal Tumor?Clinical Nuclear Medicine, 2011
- Trans‐sacral (Kraske) approach for gastrointestinal stromal tumour of the lower rectum: old procedure for a new diseaseColorectal Disease, 2008
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Journal of Surgical Oncology, 2008
- Gastrointestinal stromal tumors of the rectum: Clinical, pathologic, immunohistochemical characteristics and prognostic analysisScandinavian Journal of Gastroenterology, 2007
- Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and AnusThe American Journal of Surgical Pathology, 2001